Tekmira Reports on Voting Results From 2014 Annual Meeting of Shareholders

May 09, 2014 – Tekmira Pharmaceuticals Corporation

VANCOUVER, British Columbia, May 9, 2014 (GLOBE NEWSWIRE) — Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced the voting results from its Annual General and Special Meeting of Shareholders held Thursday May 8, 2014 in Vancouver, B.C. Shareholders voted in favor of all items of business, including the election of each of the six director nominees as follows:

Nominee

Votes For
% For
Votes Withheld
% Withheld
Peggy Phillips
7,903,418
99.79%
16,513
0.21%
Kenneth Galbraith
7,904,317
99.80%
15,614
0.20%
Don Jewell
7,906,117
99.83%
13,814
0.17%
Frank Karbe
7,904,192
99.80%
15,739
0.20%
Daniel Kisner
7,901,142
99.76%
18,789
0.24%
Mark J. Murray
7,902,367
99.78%
17,564
0.22%

About Tekmira
Tekmira Pharmaceuticals Corporation is a biopharmaceutical company focused on advancing novel RNAi therapeutics and providing its leading lipid nanoparticle delivery technology to pharmaceutical partners. Tekmira has been working in the field of nucleic acid delivery for over a decade and has broad intellectual property covering LNPs. Further information about Tekmira can be found at www.tekmira.com. Tekmira is based in Vancouver, B.C.

CONTACT:

Investors
Tekmira Investor Relations
Phone: 604-419-3200
Email: ir@tekmira.com

Media
Alan Bayless
Longview Communications Inc.
Phone: 604-694-6035
Email: abayless@longview.ca